Latest Oncology News

January 29, 2023

Adding CTX-009 to paclitaxel generated promising responses for patients with advanced biliary tract cancer when given in the second- and third-line settings.

January 28, 2023

David O’Malley, MD, discusses the mechanism of action of ubamatamab as well as findings from a phase 1 trial evaluating the agent in patients with recurrent ovarian cancer.

January 27, 2023

An investigational immunotherapy triplet combination is showing promise for the treatment of advanced solid tumors. Recruitment for the phase 2 study continues.

January 27, 2023

Elacestrant has recieved FDA approval for the treatment of patients with estrogen receptor-positive/HER2-negative advanced or metastatic breast cancer.

January 27, 2023

During a Targeted Oncology case-based roundtable event, Alan Tan, MD, discussed with participants their experience with tyrosine kinase inhibitor/immunotherapy combinations and the most recent results of triplet trials.

January 27, 2023

Based on findings from the phase 1/2 BRUIN trial, pirtobrutinib has been approved by the FDA for patients with relapsed/refractory mantle cell lymphoma.

January 27, 2023

Cilta-cel improved progression-free survival in relapsed/refractory multiple myeloma, according to findings from the first prespecified interim analysis of the phase 3 CARTITUDE-4 study.

January 27, 2023

Emma Searle, PhD, discusses results of the MajestTEC-2 trial combining teclistamab with daratumumab and lenalidomide for patients with multiple myeloma presented at the 2022 American Society of Hematology Annual Meeting and Exposition.

January 27, 2023

The latest patient enrolled in cohort 3 of the phase 1/2 MGTA-117 trial experienced a grade 5 serious adverse event resulting in death. The study has been halted to investigate the safety of the agent.

January 27, 2023

Tamibarotene has received fast track designation from the FDA for use in patients with higher-risk myelodysplastic syndrome. The agent is being further evaluated in the phase 3 SELECT MDS-1 trial.

January 27, 2023

Rachna T. Shroff, MD, MS, FASCO discussed the findings from SWOG 1815 and next steps for improving upon treatment with gemcitabine and cisplatin in biliary tract cancer.

January 27, 2023

Closing out her discussion on PD-L1–high metastatic NSCLC, Marina Chiara Garassino, MD, looks toward future evolutions in the treatment paradigm.